- Home
- DBRG vs MNKD Comparison
DBRG vs MNKD Comparison
Compare DBRG & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBRG
- MNKD
- Stock Information
- Founded
- DBRG 1991
- MNKD 1991
- Country
- DBRG United States
- MNKD United States
- Employees
- DBRG N/A
- MNKD N/A
- Industry
- DBRG Real Estate Investment Trusts
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- DBRG Real Estate
- MNKD Health Care
- Exchange
- DBRG Nasdaq
- MNKD Nasdaq
- Market Cap
- DBRG 1.9B
- MNKD 1.6B
- IPO Year
- DBRG 2009
- MNKD 2004
- Fundamental
- Price
- DBRG $8.74
- MNKD $5.00
- Analyst Decision
- DBRG Strong Buy
- MNKD Buy
- Analyst Count
- DBRG 9
- MNKD 6
- Target Price
- DBRG $16.28
- MNKD $8.92
- AVG Volume (30 Days)
- DBRG 2.8M
- MNKD 2.0M
- Earning Date
- DBRG 04-29-2025
- MNKD 05-07-2025
- Dividend Yield
- DBRG 0.45%
- MNKD N/A
- EPS Growth
- DBRG N/A
- MNKD N/A
- EPS
- DBRG 0.07
- MNKD 0.10
- Revenue
- DBRG $595,142,000.00
- MNKD $285,504,000.00
- Revenue This Year
- DBRG N/A
- MNKD $14.66
- Revenue Next Year
- DBRG $9.57
- MNKD $14.27
- P/E Ratio
- DBRG $49.28
- MNKD $50.30
- Revenue Growth
- DBRG N/A
- MNKD 43.50
- 52 Week Low
- DBRG $8.78
- MNKD $3.97
- 52 Week High
- DBRG $19.49
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- DBRG 31.98
- MNKD 37.28
- Support Level
- DBRG $9.20
- MNKD $5.16
- Resistance Level
- DBRG $9.58
- MNKD $5.28
- Average True Range (ATR)
- DBRG 0.32
- MNKD 0.15
- MACD
- DBRG -0.04
- MNKD 0.01
- Stochastic Oscillator
- DBRG 3.09
- MNKD 22.64
About DBRG DigitalBridge Group Inc.
DigitalBridge Group Inc is a developer of alternative asset manager dedicated to investing in digital infrastructure. The company's platform invests in and operates businesses across the digital ecosystem, including cell towers, data centres, fiber, small cells, and edge infrastructure, to provide clients with funds for digital infrastructure real estate infrastructure.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.